Literature DB >> 18304708

Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

Milan Raska1, Zina Moldoveanu, Jan Novak, Zdenek Hel, Lea Novak, Jadranka Bozja, Richard W Compans, Chinglai Yang, Jiri Mestecky.   

Abstract

The quality of immune responses induced by DNA vaccination depends on the site of DNA administration, the expression, and the properties of the encoded antigen. In the present study, we demonstrate that intravenous hydrodynamic HIV-1 envelope DNA injection resulted in high levels of expression of HIV-1 envelope antigen in the liver. When compared to the administration of DNA by i.n., i.d., i.m., and i.splenic routes, hydrodynamic vaccination induced, upon DNA boosting, levels of HIV-1 envelope-specific antibodies 40-fold higher than those elicited by the other routes tested. Hydrodynamic vaccination with 1 microg DNA induced higher humoral responses than 100 microg DNA given intramuscularly in the prime-boost regimen. High levels of envelope-specific IgG and IgA antibodies were induced in genital tract secretions after two doses of DNA followed by intranasal boosting with recombinant HIV-1 gp120 protein. Furthermore, two doses of 100 microg DNA generated interferon-gamma production in approximately 4.3+/-1.7% of CD8(+) splenocytes after in vitro stimulation with HIV-1 envelope peptides. These results demonstrate that DNA vaccines targeted to tissues with high proteosynthetic activity, such as the liver, results in enhanced immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304708      PMCID: PMC2323585          DOI: 10.1016/j.vaccine.2008.01.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  63 in total

Review 1.  The development of polyplex-based DNA vaccines.

Authors:  Kenneth Alan Howard; H Oya Alpar
Journal:  J Drug Target       Date:  2002-03       Impact factor: 5.121

2.  Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting.

Authors:  Martin A Maier; Constantin G Yannopoulos; Nazim Mohamed; Arlene Roland; Hans Fritz; V Mohan; George Just; Muthiah Manoharan
Journal:  Bioconjug Chem       Date:  2003 Jan-Feb       Impact factor: 4.774

Review 3.  Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.

Authors:  Thomas Merdan; Jindrich Kopecek; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

4.  Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop.

Authors:  M Shirai; S Kozlowski; D H Margulies; J A Berzofsky
Journal:  J Immunol       Date:  1997-04-01       Impact factor: 5.422

5.  Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.

Authors:  Manolo Rodrigo Garzón; Pedro Berraondo; Julien Crettaz; Laura Ochoa; Maria Vera; Juan Jose Lasarte; Africa Vales; Nico Van Rooijen; Juan Ruiz; Jesús Prieto; Javier Zulueta; Gloria González-Aseguinolaza
Journal:  Vaccine       Date:  2005-02-03       Impact factor: 3.641

6.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  11 in total

1.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 2.  Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design.

Authors:  Jiri Mestecky; Milan Raska; Jan Novak; Rashada C Alexander; Zina Moldoveanu
Journal:  J Reprod Immunol       Date:  2010-03-16       Impact factor: 4.054

3.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

4.  Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles.

Authors:  Audra A Hargett; Qing Wei; Barbora Knoppova; Stacy Hall; Zhi-Qiang Huang; Amol Prakash; Todd J Green; Zina Moldoveanu; Milan Raska; Jan Novak; Matthew B Renfrow
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

5.  Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.

Authors:  Milan Kuchař; Petr Kosztyu; Veronika Daniel Lišková; Jiří Černý; Hana Petroková; Eliška Vróblová; Michal Malý; Lucie Vaňková; Michal Křupka; Leona Rašková Kafková; Pavlína Turánek Knotigová; Jarmila Dušková; Jan Dohnálek; Josef Mašek; Jaroslav Turánek; Milan Raška; Petr Malý
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

6.  Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.

Authors:  Anthony D Cristillo; Maria Grazia Ferrari; Lauren Hudacik; Brad Lewis; Lindsey Galmin; Britany Bowen; DeVon Thompson; Nikolai Petrovsky; Phillip Markham; Ranajit Pal
Journal:  J Gen Virol       Date:  2011-01       Impact factor: 3.891

Review 7.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

8.  Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.

Authors:  Milan Raska; Lydie Czernekova; Zina Moldoveanu; Katerina Zachova; Matt C Elliott; Zdenek Novak; Stacy Hall; Michael Hoelscher; Leonard Maboko; Rhubell Brown; Phillip D Smith; Jiri Mestecky; Jan Novak
Journal:  AIDS Res Ther       Date:  2014-08-01       Impact factor: 2.250

Review 9.  Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases.

Authors:  Mei Huang; Rui Sun; Qiang Huang; Zhigang Tian
Journal:  Front Pharmacol       Date:  2017-08-30       Impact factor: 5.810

10.  Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.

Authors:  Petr Kosztyu; Milan Kuchar; Jiri Cerny; Lucia Barkocziova; Michal Maly; Hana Petrokova; Lydie Czernekova; Veronika Liskova; Leona Raskova Kafkova; Pavlina Knotigova; Josef Masek; Jaroslav Turanek; Petr Maly; Milan Raska
Journal:  EBioMedicine       Date:  2019-09       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.